Diligence memo · auto-generated · as of July 2, 2026
Cingulate Inc.
Cingulate Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Cingulate Inc. operates in Pharmaceuticals, based in KANSAS CITY.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cingulate Inc. has raised $220M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $220M on 2021-09-28.
Most recent recorded round closed around 2021-09-28.
Valuation (modeled)modeled
Provath models Cingulate Inc. at approximately $5.4B (range $1.0B–$10.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.45× the median modeled value of Series D+ Pharmaceuticals companies in 2019–2021 (15 peers) — value vs value, same stage and era. Within the normal band (145% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 4.8 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 97% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Nuvation Bio Inc., Recursion Pharmaceuticals, Inc., Vyripharm Enterprises, Inc., Verona Pharma plc, Day One Biopharmaceuticals Holding Co LLC.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.